• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases.

作者信息

Cheng Franco Wing Tak, Fan Min, Wong Carlos King Ho, Chui Celine Sze Ling, Lai Francisco Tsz Tsun, Li Xue, Wan Eric Yuk Fai, Tang Sydney Chi Wai, Chan Esther Wai Yin, Wong Ian Chi Kei

机构信息

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China.

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Sha Tin, Hong Kong SAR, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

出版信息

Kidney Int. 2022 Oct;102(4):922-925. doi: 10.1016/j.kint.2022.07.018. Epub 2022 Aug 11.

DOI:10.1016/j.kint.2022.07.018
PMID:35964798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9367175/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26a2/9367175/e5f44393f08a/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26a2/9367175/e5f44393f08a/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26a2/9367175/e5f44393f08a/fx1_lrg.jpg

相似文献

1
The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases.mRNA（BNT162b2）和灭活（科兴新冠疫苗）新冠疫苗在慢性肾脏病患者中的有效性和安全性。
Kidney Int. 2022 Oct;102(4):922-925. doi: 10.1016/j.kint.2022.07.018. Epub 2022 Aug 11.
2
Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.甲状腺功能减退症患者接种灭活新冠疫苗和 mRNA 新冠疫苗的安全性：一项基于人群的队列研究。
Thyroid. 2022 May;32(5):505-514. doi: 10.1089/thy.2021.0684. Epub 2022 Apr 7.
3
Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients.mRNA 和灭活 COVID-19 疫苗相关甲状腺功能障碍的风险：一项 230 万疫苗接种者的基于人群的研究。
BMC Med. 2022 Oct 14;20(1):339. doi: 10.1186/s12916-022-02548-1.
4
Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).接种两剂信使核糖核酸疫苗（BNT162b2）和灭活病毒疫苗（科兴新冠疫苗）后发生的结核病
J Infect. 2023 Mar;86(3):256-308. doi: 10.1016/j.jinf.2022.12.016. Epub 2022 Dec 17.
5
COVID-19 vaccine-induced immunity: Head-to-head comparison of mRNA (BNT162b2) versus inactivated (CoronaVac) vaccines.COVID-19 疫苗诱导的免疫：mRNA（BNT162b2）与灭活（CoronaVac）疫苗的头对头比较。
Respirology. 2022 Apr;27(4):260-261. doi: 10.1111/resp.14236. Epub 2022 Feb 28.
6
Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases.mRNA 和全病毒灭活疫苗对慢性呼吸系统疾病患者 COVID-19 的疗效。
Int J Chron Obstruct Pulmon Dis. 2023 Jan 19;18:47-56. doi: 10.2147/COPD.S394101. eCollection 2023.
7
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.三剂 BNT162b2 和科兴疫苗在先天性免疫缺陷儿童和成人中的安全性和免疫原性。
Front Immunol. 2022 Sep 20;13:982155. doi: 10.3389/fimmu.2022.982155. eCollection 2022.
8
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.在巴西（Immunita-001）进行的一项为期一年的 4 期研究：两剂基础免疫方案接种灭活病毒（科兴疫苗）和 BNT162b2 异源加强针的免疫原性、有效性和安全性。
Front Immunol. 2022 Jun 9;13:918896. doi: 10.3389/fimmu.2022.918896. eCollection 2022.
9
Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.BNT162b2 疫苗和科兴新冠疫苗的免疫原性和反应原性相关性。
mSphere. 2022 Apr 27;7(2):e0091521. doi: 10.1128/msphere.00915-21. Epub 2022 Mar 14.
10
Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines.比较接受 mRNA 或新冠灭活疫苗的 2 型糖尿病患者的 B 细胞和 T 细胞介导的免疫应答。
Front Immunol. 2022 Oct 11;13:1018393. doi: 10.3389/fimmu.2022.1018393. eCollection 2022.

引用本文的文献

1
Methodology of comparative studies on the relative effectiveness of COVID-19 vaccines: a systematic review.新冠病毒疫苗相对有效性的比较研究方法：一项系统评价
Osong Public Health Res Perspect. 2024 Oct;15(5):395-408. doi: 10.24171/j.phrp.2024.0063. Epub 2024 Oct 15.
2
COVID-19 infection and severe clinical outcomes in patients with kidney disease by vaccination status: a nationwide cohort study in Korea.接种疫苗状况对肾脏病患者 COVID-19 感染和严重临床结局的影响：韩国全国队列研究。
Epidemiol Health. 2024;46:e2024065. doi: 10.4178/epih.e2024065. Epub 2024 Jul 17.
3
The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.
奥密克戎 BA.2 变异株流行时期中国深圳市灭活新冠疫苗加强免疫对感染、传染性和传播的效果：一项回顾性队列研究。
Front Immunol. 2024 May 31;15:1359380. doi: 10.3389/fimmu.2024.1359380. eCollection 2024.
4
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19.莫努匹韦和奈玛特韦-利托那韦对新冠病毒感染的慢性肾脏病患者的疗效
Kidney Int Rep. 2024 Feb 9;9(5):1244-1253. doi: 10.1016/j.ekir.2024.02.009. eCollection 2024 May.
5
How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac.关于新冠疫苗有效性和安全性的研究是如何被评估的：一项重点关注科兴新冠疫苗的范围综述
Front Public Health. 2024 Apr 10;12:1321327. doi: 10.3389/fpubh.2024.1321327. eCollection 2024.
6
Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.中国深圳 SARS-CoV-2 奥密克戎 BA.2 变异株传播特性和灭活疫苗对传播的有效性。
Front Immunol. 2024 Jan 8;14:1290279. doi: 10.3389/fimmu.2023.1290279. eCollection 2023.
7
Vaccine Effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 in CKD.BNT162b2 和 CoronaVac 疫苗对慢性肾脏病患者中 SARS-CoV-2 奥密克戎 BA.2 的有效性。
Clin J Am Soc Nephrol. 2024 Apr 1;19(4):418-428. doi: 10.2215/CJN.0000000000000376. Epub 2023 Dec 26.
8
Outcomes of COVID-19 in kidney transplant recipients in the vaccination Era: A national multicenter cohort from Thailand.疫苗接种时代肾移植受者的COVID-19结局：来自泰国的一项全国多中心队列研究
Heliyon. 2023 Nov 24;9(12):e22811. doi: 10.1016/j.heliyon.2023.e22811. eCollection 2023 Dec.
9
Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.慢性阻塞性肺疾病和哮喘患者接种新冠病毒灭活疫苗和mRNA疫苗后的有效性及呼吸道不良事件：一项基于中国人群的研究
Drug Saf. 2024 Feb;47(2):135-146. doi: 10.1007/s40264-023-01364-7. Epub 2023 Dec 12.
10
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.中国广东奥密克戎 BA.2 感染突破性感染用灭活 COVID-19 疫苗加强接种的效果：一项队列研究。
Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023.